These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38173658)

  • 1. Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Kuwano A; Yada M; Tanaka K; Koga Y; Nagasawa S; Masumoto A; Motomura K
    Cancer Diagn Progn; 2024; 4(1):34-41. PubMed ID: 38173658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Fukushima T; Morimoto M; Kobayashi S; Ueno M; Uojima H; Hidaka H; Kusano C; Chuma M; Numata K; Tsuruya K; Arase Y; Kagawa T; Hattori N; Ikeda H; Watanabe T; Tanaka K; Maeda S
    Oncologist; 2023 Jul; 28(7):e526-e533. PubMed ID: 37023703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Suzuki K; Yasui Y; Tsuchiya K; Matsumoto H; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada-Shimizu M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Takahashi Y; Asahina Y; Okamoto R; Kurosaki M; Izumi N
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1183-1189. PubMed ID: 38494668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study.
    Nam H; Lee J; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Kim HY; Kim SH; Song MJ; Kwon JH; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Jang JW
    Liver Cancer; 2024 Aug; 13(4):413-425. PubMed ID: 39114756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
    Wang JH; Chen YY; Kee KM; Wang CC; Tsai MC; Kuo YH; Hung CH; Li WF; Lai HL; Chen YH
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.
    Dharmapuri S; Özbek U; Jethra H; Jun T; Marron TU; Saeed A; Huang YH; Muzaffar M; Pinter M; Balcar L; Fulgenzi C; Amara S; Weinmann A; Personeni N; Scheiner B; Pressiani T; Navaid M; Bengsch B; Paul S; Khan U; Bettinger D; Nishida N; Mohamed YI; Vogel A; Gampa A; Korolewicz J; Cammarota A; Kaseb A; Galle PR; Pillai A; Wang YH; Cortellini A; Kudo M; D'Alessio A; Rimassa L; Pinato DJ; Ang C
    World J Gastrointest Oncol; 2023 Nov; 15(11):1900-1912. PubMed ID: 38077640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
    Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Ohkawa K; Miyazaki M; Mita E; Ito T; Hagiwara H; Yakushijin T; Kodama T; Hikita H; Tatsumi T; Takehara T
    Hepatol Res; 2022 Mar; 52(3):298-307. PubMed ID: 34918428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
    Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Ochi H; Kurosaki M; Joko K; Mashiba T; Tamaki N; Tsuchiya K; Marusawa H; Tada T; Nakamura S; Narita R; Uchida Y; Akahane T; Kondo M; Mori N; Takaki S; Tsuji K; Kusakabe A; Furuta K; Kobashi H; Arai H; Nonogi M; Tamada T; Hasebe C; Izumi N
    Hepatol Res; 2023 Jan; 53(1):61-71. PubMed ID: 36070216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study.
    Lee PY; Oen KQX; Lim GRS; Hartono JL; Muthiah M; Huang DQ; Teo FSW; Li AY; Mak A; Chandran NS; Tan CL; Yang P; Tai ES; Ng KWP; Vijayan J; Chan YC; Tan LL; Lee MB; Chua HR; Hong WZ; Yap ES; Lim DK; Yuen YS; Chan YH; Aminkeng F; Wong ASC; Huang Y; Tay SH
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment.
    Chon YE; Cheon J; Kim H; Kang B; Ha Y; Kim DY; Hwang SG; Chon HJ; Kim BK
    Cancer Med; 2023 Feb; 12(3):2731-2738. PubMed ID: 35997637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.
    Iwasaki S; Hidaka H; Uojima H; Hashimura M; Nabeta T; Sanoyama I; Wada N; Kubota K; Nakazawa T; Shibuya A; Koizumi W
    Clin J Gastroenterol; 2021 Aug; 14(4):1233-1239. PubMed ID: 34024039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Fujimoto A; Toyokawa G; Koutake Y; Kimura S; Kawamata Y; Fukuishi K; Yamazaki K; Takeo S
    Thorac Cancer; 2021 Aug; 12(15):2198-2204. PubMed ID: 34173724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events.
    Hayashi H; Sawada K; Hasebe T; Nakajima S; Sawada J; Takiyama Y; Takiyama Y; Okumura T; Fujiya M
    Intern Med; 2022 Dec; 61(23):3497-3502. PubMed ID: 35491133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
    Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
    J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
    Matoya S; Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Kuroyanagi K; Kusakabe A; Koguchi H; Hasegawa I; Miyaki T; Tanaka Y; Kondo H; Kimura Y; Ozasa A; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H;
    Hepatol Res; 2023 Jun; 53(6):511-521. PubMed ID: 36723964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.